Enlivex Therapeutics Ltd. (ENLV)

Market Cap	23.75M
Revenue (ttm)	n/a
Net Income (ttm)	-18.93M
Shares Out	21.99M
EPS (ttm)	-0.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,195
Open	1.110
Previous Close	1.080
Day's Range	1.050 - 1.110
52-Week Range	0.810 - 4.590
Beta	0.99
Analysts	Strong Buy
Price Target	9.50 (+779.63%)
Earnings Date	Mar 28, 2025

About ENLV

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 12, 1995
• Employees: 71
• Stock Exchange: NASDAQ
• Ticker Symbol: ENLV
• Website: https://www.enlivex.com

Analyst Forecast

According to 2 analysts, the average rating for ENLV stock is "Strong Buy." The 12-month stock price forecast is $9.5, which is an increase of 779.63% from the latest price.

Price Target

$9.5

(779.63% upside)

Analyst Consensus: Strong Buy